These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30037854)

  • 1. SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.
    Fukumoto T; Magno E; Zhang R
    Mol Cancer Res; 2018 Dec; 16(12):1819-1825. PubMed ID: 30037854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
    PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
    Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
    Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
    Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
    Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
    Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
    Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
    Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models.
    Wang Y; Hoang L; Ji JX; Huntsman DG
    Annu Rev Pathol; 2020 Jan; 15():467-492. PubMed ID: 31977292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMARCA4 loss irrelevant for
    Wagner SK; Moon AS; Howitt BE; Renz M
    Gynecol Oncol Rep; 2023 Dec; 50():101305. PubMed ID: 38033359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SWI/SNF-deficient malignancies of the female genital tract.
    McCluggage WG; Stewart CJR
    Semin Diagn Pathol; 2021 May; 38(3):199-211. PubMed ID: 32978032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWI/SNF Alterations in Squamous Bladder Cancers.
    Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.
    Ma Y; Field NR; Xie T; Briscas S; Kokinogoulis EG; Skipper TS; Alghalayini A; Sarker FA; Tran N; Bowden NA; Dickson KA; Marsh DJ
    Cancers (Basel); 2024 Sep; 16(17):. PubMed ID: 39272926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
    Guan B; Wang TL; Shih IeM
    Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer.
    Vaicekauskaitė I; Sabaliauskaitė R; Lazutka JR; Jarmalaitė S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines.
    Tischkowitz M; Huang S; Banerjee S; Hague J; Hendricks WPD; Huntsman DG; Lang JD; Orlando KA; Oza AM; Pautier P; Ray-Coquard I; Trent JM; Witcher M; Witkowski L; McCluggage WG; Levine DA; Foulkes WD; Weissman BE
    Clin Cancer Res; 2020 Aug; 26(15):3908-3917. PubMed ID: 32156746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.